Results 31 to 40 of about 8,527,959 (316)

Gemcitabine: Progress in the treatment of pancreatic cancer [PDF]

, 2001
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor.
Heinemann, Volker
core   +1 more source

Investigation of the Electrochemical Interaction Behavior of DNA with 5-Fluorouracil Derivatives

International Journal of Electrochemical Science, 2011
Although many 5-Fluorouracil derivatives have been synthesized and identified, there are few reports on the interaction modes of different anti-carcinogen 5-Fluorouracil derivatives with Deoxyribonucleic acid (DNA).
Ke-jun Zhang, Wu-yi Liu
doaj   +1 more source

Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5-fluorouracil [PDF]

Anais Brasileiros de Dermatologia, 2013
BACKGROUND: Actinic keratosis is a frequent lesion which occurs in sunlight exposed areas. Diclofenac sodium and 5-Fluorouracil are effective, non-invasive and easy-to-apply topical treatment options.
Majorie Mergen Segatto, Sergio Ivan Torres Dornelles, Vera Bauer Silveira, Gabriela de Oliveira Frantz   +3 more
doaj   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment

Molecules, 2014
Cholesterol-conjugated 5-fluorouracil prodrugs were designed to be carried in vivo via low density lipoproteins (LDL) and subsequently undergo LDL-receptor-mediated internalisation into cancer cells. In vivo anti-cancer evaluation was performed using 5-
Awwad A. Radwan, Fares K. Alanazi
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Desenvolvimento e avaliação biofarmacêutica de sistemas coloidais como carreadores para a administração ocular do agente antitumoral 5-fluorouracil [PDF]

, 2006
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-graduação em FarmáciaO potencial das nanopartículas poliméricas em aumentar as oportunidades de absorção corneal após a administração tópica na ...
Reus, Márcia
core  

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin

, 2017
Background: 5-fluorouracil (5-FU) and cisplatin (CDDP) are used to enhance radiotherapy (RT) effect for head and neck (HN) cancers. However, the effect of local RT on systemic chemotherapeutics remains unclear.
Hsieh, Chen-Hsi;Hou, Mei-Ling;Chiang, Meng-Hsuan;Tai, Hung-Chi;Tien, Hui-Ju;Wang, Li-Ying;Tsai, Tung-Hu;Chen, Yu-Jen, 王儷穎   +1 more
core   +1 more source

PFKP is upregulated in 5-fluorouracil-resistant patients and suppresses the antitumor activity of 5-fluorouracil in colorectal cancer in vitro and in vivo

, 2023
As a long-established chemotherapy drug, 5-fluorouracil (5-FU) is widely used to clinically manage colorectal cancer (CRC). However, a substantial portion of patients develop 5-FU resistance at some stage, which poses a great challenge.
Wen Liu (39804), Lili Deng (152262), Yan Zhao (58882)   +2 more
core   +1 more source